Experts in health economics,pricing and reimbursement

Experts in health economics,
pricing and reimbursement

PHMR is an international team of highly qualified health economists and research scientists

The carefully curated multidisciplinary team at PHMR is comprised of highly qualified health economists and research scientists. This international collective of dedicated professionals provides in depth understanding of global markets and the capacity to work seamlessly in local languages.

Their combined insight from extensive industry specific experience in global pharmaceutical companies, academic positions and health economics consultancies ensures that PHMR’s clients always receive reliable, expert advice.

Mark Ratcliffe

Mark is the founder of PHMR and has developed the company into a successful health economics, pricing and market access consultancy working with a range of top 10 pharma companies. He has a vast amount of experience in the health economics, pricing, reimbursement and market access fields. He also possesses decades of experience with major international pharmaceutical companies and previous work in senior economics research positions.

Louise Longworth

Louise has 20 years of experience in health economics, health technology assessment and health outcomes and an in-depth knowledge of the methods of HTA. She has advised clients on HTA strategy and evidence generation in a diverse range of clinical areas. Louise has specialist experience in the area of outcome measurement and valuation. She has been a member of the EuroQol Group, the organisation responsible for the development of the EQ-5D instruments, for most of her career and currently holds a position on the Board of Directors.

Jeremy Morgan

Jeremy has extensive experience in leading large national, regional and global commercial operations in major pharmaceutical companies. Jeremy brings a wealth of experience to his role at PHMR, providing strategic advice to our clients on commercialisation at all stages of product development, from initial clinical development, to launch, to late lifecycle. He is an expert in commercial strategy development and operational execution. Most recently he led the launches of multiple new diabetes therapies across Europe, Japan, Canada and Australia including novel proteins and biosimilars.

Cormac Sammon

Cormac is an epidemiologist with several years’ experience of successfully delivering observational research projects for a variety of clients. His work has utilised real world data to contribute across the drug development process from establishing the clinical and economic burden of disease, to informing key parameters of cost-effectiveness models and monitoring the long term post-marketing safety and effectiveness of drugs. He has been published extensively across a range of clinical, therapeutic and methodological areas.

Koonal Shah

Koonal is a health economist with expertise in stated preference methods, the measurement and valuation of health, and the use of social value judgements in HTA decision making. He has published extensively on HTA policy, particularly on the assessment of cancer and end of life treatments. He has led research and consulting projects for a diverse range of funders and clients including global pharmaceutical companies, health care providers, policy makers, charities and research foundations. Koonal is a member of the EuroQol Group (an international network of researchers that developed the EQ-5D family of instruments) and currently serves on the Group’s Executive Committee.

Donna Fountain

Donna has managed and delivered a wide range of projects to help pharmaceutical companies with their health economics and outcomes research needs as well as maximising market access/reimbursement for new pharmaceutical and diagnostic interventions. She has a proven history of successfully leading on client projects and performing effectively at all stages of the project cycle.

Matt Glover

Matt is a health economist with extensive experience in conducting economic evaluations of new treatments and specialises in long-term modelling, with knowledge of a variety of software and conceptual models. He has contributed to and advised biopharma clients on submissions to a number of HTA agencies. He has also contributed health economic input to the design of numerous randomised controlled trials and analysed and synthesised trial data.

Vlad Berdunov

Vlad is health economist with substantial experience of leading cost-effectiveness and budget impact modelling projects. He holds extensive knowledge of statistical methods applicable to economic evaluation through his experience in trial-based economic evaluation and decision-analytic modelling to support HTA submissions. Vlad holds expertise in long-term modelling in rare diseases, including therapeutic areas with sparse evidence of long-term costs and benefits of treatment. His other research interests include the application of propensity scores to adjust for confounding in observational studies and the use of indirect comparisons of efficacy of treatments in the absence of head-to-head trials.

Megan Besford

Megan has extensive experience working across a variety of stages of the drug development process, ranging from analysis of Phase I and III clinical trial data to conducting systematic literature reviews and network meta-analyses for health technology assessment submissions. Megan is familiar with a wide range of common and novel statistical methods used in the pharmaceutical industry and has experience using both frequentist and Bayesian frameworks. She is also proficient with a wide range of programming languages, including SAS, R and WinBUGs.

Lynsey Boyce

Rebecca Brown

Rebecca has a background in medical writing and horizon scanning for HTA organisations as part of a national horizon scanning centre. She has experience of conducting systematic reviews, from conception to completion, planning and conducting a clinical trial and preparing oral and poster presentations for a variety of audiences. Rebecca has experience in several disease areas including musculoskeletal health, nutrition and gastrointestinal disease.

Gintare Cepinskaite

Gintare’s journey at PHMR began in 2013 when she joined the company as Administrative Assistant to help establish the Newcastle upon Tyne (UK) office. Currently she is part of the team providing support to the growth of the company by keeping HR operations aligned to the company values. Gintare is passionate about her role and she strongly believes that positive working relationships are the foundation for any kind of success. In her spare time Gintare attends art exhibitions, goes on contemporary theatre breaks, reads world literature and enjoys outdoor trips, especially if foraging is on the agenda.

Jasmine Farrington

Jasmine’s main responsibility at PHMR is in project delivery and management for a range of activities in health economics, outcomes research and market access. Jasmine also contributes to PHMR’s operations and enjoys optimising organisation and communication for our projects to progress rapidly, efficiently and to the highest standards. She has an interest in HTA processes, market access and novel reimbursement frameworks for therapeutics with innovative mechanisms and those based on cell and gene therapies. Jasmine has over 10 years of experience in pharmacology, having previously worked in the UK and Europe for two world leading pharmaceutical companies. She has publications in several peer-reviewed journals and has presented at a range of international conferences. Jasmine has experience in the therapeutic fields of inflammation, allergy, stem cell therapies, oncology, pain and neuroscience.

India Flint

India joined PHMR having successfully completed her MSc in Health Economics at the University of York. She has since been involved and managed a range of projects at PHMR, including patient reported outcomes analysis and the development and execution of feasibility assessments. She has also supported the building and reviewing of economic models e.g. cost-effectiveness and budget impact models. Before PHMR, India also worked with the Health Economics team at Public Health England, where she submitted her MSc thesis on the investigation of health and social care costs of common chronic conditions in England.

Lefteris Floros

Lefteris carries broad knowledge in health economics having served in multiple academic and commercial positions. He holds great experience with the collection, evaluation, and modelling of clinical and cost data having designed numerous clinical trial based economic evaluations and having led the development of multiple economic models for HTA submission purposes. He also carries great familiarity with HTA agency processes having been part of the technical teams supporting expert committees of UK NICE clinical guidelines.

Daniella Foster

Daniella recently completed an MRes in Biotechnology and Business Enterprise at Newcastle University, during which she conducted a laboratory-based research project investigating the chemical modification of antibiotics used to treat drug-resistant tuberculosis. This experience allowed her to develop skills including performing literature reviews, analysing qualitative and quantitative data, and presenting posters & presentations. Since joining PHMR, Daniella has been involved in the development of literature reviews, scientific reports and global value dossiers.

Dave Fox

Dave has considerable experience in the information and library field supporting health research. He is responsible for designing literature searches and strategies to support the wide variety of projects and research that PHMR undertakes and managing the results of searches using reference management software. He has run literature searches to support numerous reviews including NICE single and multiple technology assessments, Cochrane reviews, Public Health Research Council projects, and British Thoracic Society clinical guidelines.

Louise Francis

Louise is a PhD-trained researcher who has extensive experience of conducting systematic reviews and meta-analyses alongside online surveys. She has produced and presented multiple posters and presentations at scientific conferences in the area of nutrition. Prior to joining the PHMR team, Louise completed her thesis at Northumbria University investigating the use of the Mediterranean diet in combination with intermittent fasting in the treatment and prevention of obesity. This data was subsequently used to inform the pilot study of a randomised controlled trial aiming to understand the feasibility of these dietary patterns in daily life and their impact on body composition and cardiovascular biomarkers.

Adam Gibson

Adam’s role at PHMR includes leading a range of health economics and outcomes projects including health valuation, utility measurement, analysis of outcomes data, development of patient-reported outcome measures, and psychometric testing. Adam is a PhD trained researcher with over five years of academic and consultancy research experience, where he has developed valuable knowledge of clinical outcomes, as well as HTA methods and processes. His research interests include exploring patient and caregiver outcomes using mixed-methods approaches. He has published and presented research on patients’ treatment experiences at international conferences and in peer-reviewed journals.

Nicola Illingworth

Nicola has conducted focussed and pragmatic literature reviews and contributed to projects on clinical trial design and burden of illness studies, global HTA strategies and the use of patient reported outcome measures in HTA. Nicola has extensive experience in clinical trial method development and has developed skills in data extraction and data management, presenting reports in the form of slide decks or word documents, as well the preparation of manuscripts and posters.

Persefoni Ioannou

Persefoni has a strong background in the field of medical writing with extensive experience in proofreading, quality assessment of publications and data extractions. Since starting work at PHMR, she has been involved in a range of projects, including preparation of manuscripts, pragmatic literature reviews, early pipeline assessments, global value dossiers and health technology assessment reviews. Persefoni has worked in a range of disease areas, including musculoskeletal diseases, gastrointestinal diseases, mental disorders and haematologic malignancies.

Gabriel Jones

Gabriel has experience in conducting multiple stages of systematic reviews from protocol development through to interpretation and communication of results in written format. He has contributed to reviews across a wide range of therapeutic areas which have been used to support strategic drug development, value message development, economic modelling, and to inform HTA submissions. In addition to systematic reviews, Gabriel has contributed to the development of dossiers and materials for publication and congress activities.

Ewan Laws

Ewan is a health economist with experience in survival modelling and data extrapolation using a range of traditional and novel methods. He has particular therapeutic experience working in the fields of immuno-oncologics and autoimmune diseases. Ewan also has experience conducting systematic and targeting literature reviews and quantitative data analysis.

Thomas Leahy

Thomas is a statistician and has been involved in a variety of projects using real-world data to inform decision making and insight. He has worked with a variety of frequentist and Bayesian modelling approaches with complex spatio-temporal data using state-of-the-art MCMC fitting procedures. He is proficient in R and Python. Currently, he is completing his PhD at Imperial College London after having a varied background in mathematics and statistics with applications in various areas. He has presented at conferences and workshops nationally and internationally and is published in peer-reviewed journals.

Andrew Lenny

Andrew is a health economist who holds an MSc in Health Economics from the University of York. Andrew joined PHMR prior to the successful completion of his thesis on the sensitivity of generic quality of life measures to worsening levels of pain and sleep in adults suffering from rare musculoskeletal diseases. During his time here, he has collaborated on, and project managed, several health outcomes-related projects involving PRO development and utility measurement for a variety of clients. Additionally, he holds a BA in Economics and has previous work experience in the stock brokerage industry.

Helen Lilley

Helen is experienced in conducting systematic and pragmatic literature reviews (clinical and economic), and in developing value messages and global value dossiers. She has worked in the fields of immunology, molecular biology, physiology, and cell biology research. Helen has written and edited a wide range of medical documents, including published manuscripts, posters and oral presentations.

Ping-Ru Lo

Ping has been with PHMR since its foundation helping it develop into a successful health economics, pricing and market access consultancy. Coming from a background in clinical pharmacy both in Germany and the UK, she has changed direction in order to lead the contracting and finance team and set up the internal project management structure.

Aurelie Meunier

Aurelie is a health economist with experience of adapting and developing full cost-effectiveness models and budget impact models in various disease areas for HTA submission purposes. Aurelie has also contributed to projects of measurement and valuation of health-outcomes, developing mapping algorithms to generate utility data to inform cost-utility analysis. Prior to joining PHMR she conducted evaluative academic research on health policy in Australia, gaining experience in data analysis using econometrics methods, additionally she has previous work experience in marketing in the pharmaceutical industry.

Rachael Miller

Rachael has been involved with a range of projects at PHMR and has experience conducting multiple stages of systematic reviews and working with meta-analyses. Previous experience in clinical trial management has also allowed her to develop skills in stringent data analysis, leadership and communication with commercial and academic sponsors, as well as clinical trial patients.

Anne-Sophie Moutié

Anne-Sophie has a wide-ranging experience of health economics and HTA in a range of settings including consultancies, hospitals, pharmaceutical companies and governmental bodies. Such wide-ranging experience has provided her with an in-depth understanding of HTA and reimbursement of pharmaceuticals. Anne-Sophie has developed many HTA submissions for the French HAS (Haute Autorité de Santé) for a range of new therapies including for oncology and orphan designation treatments on behalf of leading pharmaceutical companies. Prior to joining PHMR, Anne-Sophie worked at the Health Products Economics Committee (CEPS) of the French Ministry of Health where she developed valuable insight and experience in pricing processes and negotiations, and evaluation of economic dossiers.

Rachel Payne

Rachel has been involved in a range of projects at PHMR, including systematic and pragmatic literature reviews, advisory boards, HTA submissions and the preparation of a wide range of value communication documents. She has experience in the therapeutic areas of IBD, AAV and CKD, and extensive experience in nutraceuticals research prior to joining PHMR. She has prepared manuscripts for publication in high impact peer-reviewed research journals and presented at international conferences.

Ally Robert

While at PHMR, Ally has been involved in supporting targeted and systematic literature reviews, gathering and interpreting data and communicating complex information in the form of slide decks and scientific reports. She has experience in multiple project types including reviews of clinical efficacy, economic evaluations and burden of illness, HTA process reviews, and production of slide decks for training and educational use. She has disease area experience in oncology, muscle wasting, and rare diseases. Prior to joining PHMR, Ally worked in the pharmaceutical industry as a project manager and holds a PhD in cellular biology and tissue engineering.

Philip Ruane

Philip has been involved in a range of projects at PHMR, predominantly involving systematic literature reviews. He has experience in conducting various aspects of systematic reviews including data extraction and interpretation, and the communication of results for value message development, HTAs, and external publication. Philip has contributed to reviews focusing on the clinical effectiveness of interventions, and the burden of chronic conditions on patients and their caregivers, and has experience in several disease areas including respiratory disease, sleep disorders, and toxicology.

Caroline Shaw

Caroline has been involved in conducting systematic and pragmatic literature reviews of clinical efficacy, economic evaluations, health-related quality of life and burden of illness, to support market access strategies. She has experience in all aspects of the review process, including developing protocols, screening, data extraction and report writing. She has also conducted primary market research with payers and KOLs to assess market access opportunities. Before joining PHMR, Caroline worked in academia in public health research, where she performed observational and interventional studies, as well as systematic and scoping reviews.

Alexandra Soare

Alexandra is a health economics and outcomes researcher with experience in health valuation, utility measurement, patient reported outcomes analysis and mapping studies. She joined PHMR after successfully completing her MSc in Health Economics and Decision Modelling at the University of Sheffield. Her MSc dissertation project compared a partitioned survival model and a Markov model in terms of the results in advanced non-small cell lung cancer.

Elaine Stamp

Elaine is a medical statistician with extensive experience of statistical input into clinical trials and large public health projects. She possesses experience in analysis of trial data using advanced techniques, merging large patient data sets to assess public health interventions and is fully compliant with Good Clinical Practice (GCP) with up to date certification. This includes contributing to study design, protocol development and the writing of Statistical Analysis Plans (SAPs) as well as the analysis of data using a wide variety of statistical techniques.

Craig Tallentire

Craig is experienced in conducting systematic literature reviews, performing quantitative data analyses and writing peer-reviewed manuscripts. His previous research was interdisciplinary, with topics grounded in both life and environmental sciences. Since joining PHMR, Craig has contributed to a number of projects in support of market access and reimbursement activities, including value communications projects, systematic literature reviews of clinical efficacy of interventions and economic evidence (i.e. economic evaluations, health related quality of life, cost and healthcare resource use), and epidemiology reviews.

Dimitris Tzelis

Dimitris is a health economist, with broad experience in economic evaluations of therapeutic and diagnostic interventions. He has led and contributed to the conceptualisation and development of long-term models, in a wide range of software, and has completed projects for a diverse range of funders and clients including research foundations, pharmaceutical, and medical device companies.
He also has conducted systematic literature reviews, and diagnostic meta-analyses, and has broad knowledge of HTA methods and processes. His work covers a wide range of disease areas including oncology, mental health, and metabolic diseases.

Sophie Walker

Sophie joined PHMR after completing an MRes in Ageing and Health at Newcastle University and contributes to a variety of projects in support of market access and reimbursement. Sophie is experienced in conducting systematic literature reviews and HTA reviews, and in developing global value dossiers. She has produced and edited peer-reviewed manuscripts, slide decks and posters, and has experience of presenting her work at international conferences. Previous experience in patient and public involvement research has allowed Sophie to develop skills in qualitative research planning and in facilitating focus groups.

Catherine Watson

Catherine’s main responsibility at PHMR is focussed on undertaking pragmatic and systematic literature reviews. Prior to joining PHMR, Catherine worked for 15 years in clinical trial management in an academic and commercial trial environment and was involved in Phase II/III trials across different therapeutic areas. She has developed skills in data monitoring, communication with commercial and academic sponsors and preparing/submitting complex study documentation. During her PhD, she prepared manuscripts for publication and has presented at international conferences.

Tibi

Tibi has a part-time role at PHMR. She has expertise in methods for improving health and wellbeing outcomes in workplace settings. Outside of PHMR, Tibi can usually be found networking at nearby Hampstead Heath.

Market access alerts

Our market access alerts are hand-picked items of breaking pricing, reimbursement and market access news.

Alerts